Market research
DHR Danaher Corporation
Current ticker: DHR
NYSE USD Healthcare
Latest close
As of 28 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 157B
- P/E ratio
- 39.72
- Analyst target
- 242.7727
- Dividend yield
- 0.6%
- Beta
- 0.8
Profile
Instrument facts
- Exchange
- NYSE
- Currency
- USD
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- Not available
- Market cap
- 157B
- P/E ratio
- 39.72
- Analyst target
- 242.7727
- Dividend yield
- 0.6%
- Beta
- 0.8
About
About Danaher Corporation
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
Research context
Danaher Corporation appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Diagnostics & Research
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
5 comments
Sign in to join the DHR discussion.
5 years, 6 months ago
Danaher Corporation is currently in a long term uptrend where the price is trading 17.2% above its 200 day moving average.
From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 7.3.
Danaher Corporation's total revenue rose by 138.3% to $7B since the same quarter in the previous year.
Its net income has dropped by 2.7% to $1B since the same quarter in the previous year.
Finally, its free cash flow grew by 91.7% to $2B since the same quarter in the previous year.
Based on the above factors, Danaher Corporation gets an overall score of 4/5.
5 years, 9 months ago
5 years, 9 months ago
5 years, 9 months ago
5 years, 10 months ago